PINK BISMUTH PLUS ANTACID RELIEF TABLETS 262 MG
BISMUTH SUBSALICYLATE : 262 MG CALCIUM CARBONATE : 495 MG · DIN 02219204 · PERRIGO INTERNATIONAL
Health Canada status: CANCELLED POST MARKET
What is PINK BISMUTH PLUS ANTACID RELIEF TABLETS?
PINK BISMUTH PLUS ANTACID RELIEF TABLETS 262 MG contains BISMUTH SUBSALICYLATE : 262 MG CALCIUM CARBONATE : 495 MG. It is listed in the Health Canada Drug Product Database under DIN 02219204, held by PERRIGO INTERNATIONAL, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Oct-2000. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02219204 |
|---|---|
| Brand name | PINK BISMUTH PLUS ANTACID RELIEF TABLETS |
| Generic / active ingredient | BISMUTH SUBSALICYLATE : 262 MG CALCIUM CARBONATE : 495 MG |
| Manufacturer | PERRIGO INTERNATIONAL |
| Strength | 262 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A02AX ANTACIDS, OTHER COMBINATIONS |
| AHFS class | 56:04.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 10-Oct-2000 |
| Original market date | 1997-09-29 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A02AX ANTACIDS, OTHER COMBINATIONS. 2 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PEPTO-BISMOL CHEWABLES | 350 MG | TABLET (CHEWABLE) | PROCTER & GAMBLE INC | MARKETED | DIN 02237315 |
| STOMACH RELIEF CHEWABLE TABLETS | 262 MG | TABLET (CHEWABLE) | GUARDIAN DRUG COMPANY INC | MARKETED | DIN 02389215 |
| ANTACID 2 TABLETS | 61 MG | TABLET | ADVERTISING UNLIMITED INC. (A.U.I.) | CANCELLED POST MARKET | DIN 01904310 |
| BISMED CHEWABLE TABLETS | 350 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED POST MARKET | DIN 00810509 |
| BISMUTH + ANTACID (CHEWABLE TABLETS) | 262 MG | TABLET (CHEWABLE) | PERRIGO INTERNATIONAL | CANCELLED POST MARKET | DIN 02240473 |
| BISMUTH CHEWABLE TABLETS | 308 MG | TABLET | VITA HEALTH PRODUCTS INC | CANCELLED POST MARKET | DIN 02243124 |
| BISMUTH TABLETS WITH CALCIUM CARBONATE | 350 MG | TABLET (CHEWABLE) | TANTA PHARMACEUTICALS INC | APPROVED | DIN 02317117 |
| CHERRY FLAVOUR PEPTO-BISMOL TAB | 262 MG | TABLET | PROCTER & GAMBLE INC | CANCELLED POST MARKET | DIN 01983725 |
| CHEWABLE BISMUTH TABLETS WITH CALCIUM CARBONATE | 262 MG | TABLET (CHEWABLE) | CELLCHEM PHARMACEUTICALS INC. | DORMANT | DIN 02319888 |
| MUCAINE - SUS | 100 MG / 5 ML | SUSPENSION | AURIUM PHARMA INC. | CANCELLED POST MARKET | DIN 02125013 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.